SOURCE: Naviscan

Naviscan

January 31, 2012 00:00 ET

First Naviscan PET Scanner Installed in Turkey

Positron Emission Mammography Now Available at MEDICA Medical Center

SAN DIEGO, CA--(Marketwire - Jan 31, 2012) - A Naviscan PET scanner performing Positron Emission Mammography (PEM) has been installed at the prestigious MEDICA Medical Center in Istanbul, Turkey. Capitalizing on Naviscan's distribution in 13 European countries, this marks the first installation of a backlog of orders in the European market.

"After PET/CT that has capability of N and M staging capability on breast cancer, PEM is a powerful tool to define T staging with high sensitivity and specificity," said Dr. Okan Falay, Nuclear Medicine Chief at MEDICA Medical Center. "In recent years due to increased breast-conserving surgery, neoadjuvant treatment has become a therapy choice because of locally advanced cancer and possibility of locoregional recurrence. PEM can give information much earlier than MRI and mammography as a routine diagnostic method about therapy monitoring and recurrence."

PEM imaging shows the location as well as the metabolic phase of a lesion. This information is critical in determining whether a lesion is malignant and influences the course of treatment by providing an ability to distinguish between benign and malignant lesions, what researchers term "specificity." Recent studies have demonstrated that PEM has similar sensitivity and higher specificity than breast MRI. The scanner is the only FDA-cleared, CE-certified 3D Molecular Breast Imaging (MBI) device on the market with biopsy-guidance.

About Naviscan, Inc.

Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the U.S. and is globally distributed in 34 countries. The Company is headquartered in San Diego, California and is the first to obtain FDA clearance and CE Mark for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance.

Contact Information

  • Contact Information
    Guillaume Bailliard
    Executive Vice President
    Naviscan, Inc.
    Tel: +1.858.332.0941
    Email Contact

    Joleen Schultz
    Naviscan Marketing Communications
    321 Medical Launch
    Tel: +1.858.455.5500
    Email Contact